Kuickresearch::Industry News

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

University of Michigan Researchers to Develop Potent Small Molecule Inhibitors for Cancer Treatment

Release Date: 22 November 2020

Researchers from one of the elite universities are focused towards development of first drug compounds that is capable of inhibiting a group of enzymes which is associated with different types of cancers such as childhood leukemia. As pe...

Read More


Different Targeted Therapies Evolving Faster than any other Traditional Therapy for Lung Cancer

Release Date: 22 November 2020

Lung cancer is one of the most frequent types of cancer diagnosed across the globe and subsequently MET inhibition for the lung cancer is among the latest forms of treatment found for it. The MET inhibition targeted treatment for the lun...

Read More


Selpercatinib to Show Durable Response in Lung Cancer and Thyroid Cancer Treatment

Release Date: 22 November 2020

In the patients suffering from non-small cell lung cancer which were marked by RET gene fusions, the drug selpercatinib is observed to be well-tolerated as well as is successful in developing durable objective response and tumor shrinkag...

Read More


Immune Checkpoint Inhibitors to Increase Cardiovascular Diseases in the Patients

Release Date: 22 November 2020

A novel study indicates that a typical type of cancer treatment that aims at boosting the immune system of the body may have a bad impact on worsening the inflammation in the arteries that distribute blood from the heart to other parts o...

Read More


Combinational Impact of HDAC and mTOR Associated with Promising Results

Release Date: 22 November 2020

For patients suffering from relapsed/refractory Hodgkin lymphoma, vorinostat and an mTOR inhibitor combination were observed to deliver positive impact in the form of high response rate on the patients. The study was conducted for novel ...

Read More


Researchers Inclined towards Optimizing Novel BRAF Inhibitors against Advanced Cancers

Release Date: 21 November 2020

A novel drug developed by the researchers is estimated to show high anti-cancer activity in the patients that have altered BRAF gene. In the respective clinical trial that was focused towards the development of novel drug included 75 pat...

Read More


Phase II Clinical Research Expand the Applications of Ipilimumab and Nivolumab in Prostate Cancer Patients

Release Date: 21 November 2020

The clinical outcome of the phase II led by the researchers from the Texas University have concluded that the combination of the drug ipilimumab and nivolumab could generate potential result in the patients suffering from metastatic cast...

Read More


Combinational Therapy to Overcome Refractory Hodgkin Lymphoma Challenges at Global Level

Release Date: 21 November 2020

A novel study approaches the evaluation of Zolinza in combination with other drug i.e. Rapamune or Afinitor for the treatment of the patients suffering from relapsed Hodgkin Lymphoma. There was a clinical efficacy recorded in the patient...

Read More


Novel PARP Inhibitors Boosting the Activity of Chemotherapy and Radiation Therapy

Release Date: 21 November 2020

There are hundreds of cancer types in the world and the discovery of PARP inhibitors have remained successful in transforming the treatment strategy of breast, ovarian as well as prostate cancer. The researchers involved in the developme...

Read More


Bladder Cancer to get Evaluated for Proton Pump Inhibitors

Release Date: 21 November 2020

A recent study is focused towards the patients who have been suffering from advanced urothelial carcinoma. As per the researchers who conducted the research study, proton pump inhibitor could be used as a negative prognostic marker in th...

Read More


Colorectal Cancer Patients to Receive Potent PDE5 Inhibitors as an Effective Treatment

Release Date: 21 November 2020

Researchers are pointing towards the potential of expanding phosphodiesterase-5 inhibitor drugs so that the efficacy of the treatment of the patients suffering from colorectal cancer could be enhanced. It is observed by the researchers t...

Read More


Nanobiologics and Immunotherapy to Evolve the Entire Cancer Therapeutics 180 Degrees

Release Date: 21 November 2020

In the current state of pharmaceutical industry, T cells for the eradication of the cancer cells is considered as one of the most strategically important for the cancer cells. A group of researchers have identified a nanobiologic that co...

Read More


Immune Checkpoint Inhibitor Combination with Chemotherapeutic Drug to Improve the Overall Survival Rate of Breast Cancer Patients

Release Date: 20 November 2020

A novel cancer study indicates that adding a potent immunotherapy drug to the three-drug chemotherapy regimen carries the ability to treat the patients suffering from triple-negative breast cancer. To prove the clinical research study, r...

Read More


Clinical Study Indicates towards Progressive State of Selpercatinib against Medullary Thyroid Cancer

Release Date: 20 November 2020

As per the clinical outcomes associated with Selpercatinib treatment of RET-altered thyroid cancer, the drug is linked with tolerable safety profile and high response and progression-free survival (PFS) rates. The research with respect to the clinical s...

Read More


Novel Model to Accurately Predict the Response Generated by Immunotherapy in Lung Cancer

Release Date: 20 November 2020

Selecting the correct treatment regimen for non-small cell lung cancer is estimated to be quite important for the overall treatment efficiency. According to the researchers, biomarkers can effectively change during therapy leading to change in the treatment procedure...

Read More


1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

Need custom market research solution? We can help you with that too.